Eli Lilly CEO David Reeks warned that Trump's decision to impose broad tariffs could eventually damage drug development in the pharmaceutical industry. Trump's reciprocal tariffs exempted pharmaceuticals imported into the US, which gave pharmaceutical companies a sigh of relief. But industry leaders are still preparing for Trump's upcoming drug tariff plan. In an interview on Friday, Rix said, “We can't break these agreements, so we have to bear the cost of tariffs and make trade-offs within the company. Normally, this will result in layoffs or cuts in R&D investment, and I expect R&D to bear the brunt. It was a disappointing result.”

Eli Lilly CEO David Reeks warned that Trump's decision to impose broad tariffs could eventually damage drug development in the pharmaceutical industry. Trump's reciprocal tariffs exempted pharmaceuticals imported into the US, which gave pharmaceutical companies a sigh of relief. But industry leaders are still preparing for Trump's upcoming drug tariff plan. In an interview on Friday, Rix said, “We can't break these agreements, so we have to bear the cost of tariffs and make trade-offs within the company. Normally, this will result in layoffs or cuts in R&D investment, and I expect R&D to bear the brunt. It was a disappointing result.”